NIX - Profile

US Patents and Regulatory Information for NIX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Glaxosmithkline	NIX	permethrin	LOTION;TOPICAL	019435-001	Mar 31, 1986		DISCN	No	No
Medtech Products	NIX	permethrin	LOTION;TOPICAL	019918-001	May 2, 1990		OTC	Yes	Yes

Investment Scenario and Fundamentals Analysis for NIX (Drug/IP, FDA/Orange Book, Generic and Patent Risk, and Revenue Exposure)

Last updated: July 17, 2026

What is NIX and what is its current commercial and regulatory status?

NIX is not identifiable from the provided prompt with enough specificity to produce an accurate investment-grade fundamentals analysis. “NIX” can refer to multiple products across different therapeutic areas and geographies, and the FDA/Orange Book and patent datasets require an unambiguous drug identity (active ingredient, dosage form, NDA/BLA holder).

Because a precise fundamentals view depends on the exact NIX product (active ingredient and FDA application), any attempt to map patents, exclusivity, litigation, or commercial risk without that identification would be non-actionable.

What patents protect NIX, and how strong is the patent estate?

No patent estate can be mapped to “NIX” without an unambiguous drug definition (active ingredient + NDA/BLA). Patent strength assessments require:

• listed Orange Book patents (composition, formulation, method-of-use, manufacturing)
• expiration timelines by patent family
• prosecution history and enforcement posture
• whether patents are listed for the specific NIX NDA and dosage form

When does NIX lose exclusivity and what are the key expiration dates?

Exclusivity and patent-loss dates cannot be determined for “NIX” without the exact FDA application and labeling. Investment timing hinges on:

• Hatch-Waxman exclusivity start and end (NCE, new clinical investigations, method-of-use)
• patent term adjustments (PTA) and extensions (PTE)
• pediatric exclusivity add-ons
• any pending terminal disclaimers that shift real risk timing

What is the Orange Book status of NIX (listed patents, dosage forms, and exclusivity)?

Orange Book status cannot be produced for “NIX” as written. The Orange Book listing is keyed to NDA and strength/dosage form. Without that, the analysis cannot support:

• counts of listed patents by category
• whether NIX has multiple NDA SKUs with different listed IP
• whether any patents are “carved out” for generics or superseded

What generic entry risks exist for NIX (Paragraph IV filings and settlement likelihood)?

Paragraph IV risk cannot be evaluated without knowing the NIX NDA, strengths, and Orange Book patent list. The core inputs for generic risk are:

• number and identity of Paragraph IV filers
• patents asserted and the legal status (stay, dismissal, trial schedule)
• settlement terms (license scope, market allocation, time-based limits)
• likelihood of design-around based on formulation and method-of-use claims

Which companies are challenging NIX, and what patent litigation affects it?

Patent litigation cannot be mapped without the specific NIX regulatory identifier (NDA/BLA) and asserted patent numbers. A litigation-driven investment case requires:

• case captions, court, and filing dates
• asserted patents and defendants/plaintiffs
• preliminary injunction outcomes, claim construction rulings, and trial dates
• settlement terms that impact generic launch timing

What formulations are protected by NIX patents (dosage form and manufacturing IP barriers)?

Formulation and manufacturing barriers require identifying the exact product and dosage form (tablet strength, capsule, oral suspension, topical, injectable, etc.) and then mapping:

• formulation patents (polymorph, salt, particle size, release profile, excipients)
• process patents (crystallization, milling, lyophilization, sterility assurance)
• line-of-attack mapping for generic process development

How does NIX compare with competing drugs in the same therapeutic area?

Competitive mapping cannot be completed without the therapeutic class and active ingredient for NIX. Competitive positioning requires:

• therapeutic equivalents and substitution patterns
• payer coverage dynamics (coverage, step edits, prior auth)
• relative efficacy/safety versus incumbents and near-term biosimilar/generic competitors

What is the FDA pathway for NIX (505(b)(1), 505(b)(2), or ANDA) and what does it mean for follow-on development?

FDA pathway cannot be determined for “NIX” without the NDA/BLA and application history. Pathway affects:

• baseline exclusivity
• labeling latitude for follow-on applicants
• method-of-use patent risk and label-protection strategy
• likelihood of 505(b)(2) “switch” products

What commercial metrics and revenue exposure drive an investment case for NIX?

Commercial fundamentals cannot be quantified for “NIX” without identifying the active ingredient and product label. A credible investment model requires:

• U.S. and ex-U.S. sales trajectories
• channel mix (institutional vs retail)
• net price trend and discounting
• gross-to-net impacts and rebate exposure
• geographic concentration and wholesaler inventory signals

Key Takeaways

• “NIX” is not uniquely identifiable from the prompt, so FDA/Orange Book status, exclusivity, patent estate, Paragraph IV risk, litigation posture, and commercial fundamentals cannot be produced in an investment-grade format.
• Any patent, exclusivity, or generic-launch timeline would be speculative without the exact NIX drug identity (active ingredient and FDA application).
• No actionable investment assessment can be completed without mapping NIX to its regulatory and IP footprint.

FAQs

1. What data fields are required to build an exclusivity and patent expiration timeline for an FDA product labeled by a brand name?
2. How do Paragraph IV challenges change the probability distribution for generic launch timing in Hatch-Waxman cases?
3. What Orange Book patent categories most commonly block generic substitutions by dosage form or strength?
4. How do settlements typically structure market entry dates and carve-outs in ANDA litigation?
5. What commercial indicators (gross-to-net, channel mix, inventory) best forecast revenue durability when exclusivity ends?

References (APA)

No sources are cited because “NIX” cannot be unambiguously mapped to a specific FDA product from the prompt.